Fig 1.
Heparanase levels in saliva and tumor tissue specimens were investigated with immunohistochemical staining and an ELISAs.
(A) Representative images show heparanase-negative and heparanase-positive immunohistochemical staining in benign and malignant salivary gland tumors. (B) Heparanase levels in 59 benign salivary gland tumor tissues and 67 malignant tumor tissues were evaluated with immunohistochemical staining. (C) Salivary heparanase levels of 59 patients with benign salivary gland tumors, 67 patients with malignant tumors, and 25 healthy donors (normal controls) were determined using ELISAs. (D) The consistency of heparanase levels in saliva and tumor tissues from 126 patients with salivary gland tumors (59 patients with benign tumors and 67 patients with malignant tumors) were evaluated using Pearson’s correlation analysis.
Fig 2.
Correlations between salivary heparanase levels and clinicopathological parameters in patients with malignant salivary gland tumors.
The associations between salivary heparanase levels and clinicopathological parameters—age, gender, smoking history, alcohol history, lymph node metastasis, TNM stage, disease site, and tumor type—were analyzed in patients with malignant salivary gland tumors.
Fig 3.
Correlations between salivary heparanase levels and clinical outcomes in patients with malignant salivary gland tumors.
Kaplan-Meier survival curves show the (A) overall survival, and (B) disease-specific survival of patients with malignant salivary gland tumors relative to salivary heparanase levels is correlated.
Table 1.
Univariate and Multivariate Cox Proportional Hazards Regression Models for Estimating Overall Survival.